- Company
- Novartis Korea appoints Byungjae Yoo as new head
- by Eo, Yun-Ho Sep 15, 2021 06:11am
- Byungjae Yoo, the former Managing Director of Johnson & Johnson Medical North Asia, has been appointed as the new head to lead Novartis Korea. The company had recently announced through an internal notice that Yoo will be officially appointed as its General Manager from October 1st. This will be the second time since the company's esta
- Company
- Pharma companies fail to suspend renegotiations for CAs
- by Chon, Seung-Hyun Sep 15, 2021 06:11am
- Once again, the suspension of execution for the second negotiation order to retrieve reimbursement that was paid for choline alfoscerate (cholinergic agent) that was filed by pharmaceutical companies was dismissed. In other words, the companies have failed to suspend the execution of both the first and second negotiation order to retrieve
- InterView
- Leclaza’s ESMO data will determine FDA approval
- by An, Kyung-Jin Sep 15, 2021 06:11am
- "This data will be the basis for determining the approval of Leclaza combination therapy. Following Tagrisso, the world is paying attention to how much lung cancer patients who failed to treat platinum-based anticancer drugs will react. " Janssen, a partner of Yuhan, will announce new clinical data on combination therapy with Leclaza at t
- Policy
- Controversy over the price of COVID PO of ₩900,000
- by Lee, Jeong-Hwan Sep 15, 2021 06:11am
- While the government, which judged that oral treatments are needed to shift the COVID-19 phase, is negotiating pre-purchase with global pharmaceutical companies, it is pointed out that drug prices will reach &8361;900,000. The government also acknowledges that the price of oral COVID-19 treatment is expensive, but if they have a therapeut
- Company
- Who is the winner of the domestic toxin in the US market?
- by Nho, Byung Chul Sep 14, 2021 05:55am
- As Medy Tox received the rights of the improved botulinum toxin candidate MT10109L from AbbVie on the 8th, competition in the U.S. market for domestic Toxin companies is expected to intensify. The size of the US botulinum toxin market is about 2 trillion won, the largest sales in the world. For Korean companies, the United States is an ess
- Policy
- Sama Pharm’s ‘Daxas’ generic approved
- by Lee, Tak-Sun Sep 14, 2021 05:55am
- Sama Pharm received approval for the first generic of the COPD treatment ‘Daxas (roflumilast, AstraZeneca Korea)'. As Sama was the only company that succeeded in avoiding the composition patent of Daxas, if the generic is released immediately, the company will be able to preoccupy and monopolize the market for the time being. The Mini
- Policy
- Moon "Invest ₩2.2 trillion in 5 years for vaccines"
- by Lee, Tak-Sun Sep 14, 2021 05:55am
- President Moon Jae-in announced that South Korea will “invest &8361;2.2 trillion to increase its vaccine competency over the next 5 years.” On September 13th, President Moon expressed such plans in a recorded welcome address for the 'Global Bio Conference' that is being held at the Grand Intercontinental Parnas Hotel in Seoul. Moon sa
- Company
- Pharmaceutical companies lost the impurity valsartan lawsuit
- by Kim, Jin-Gu Sep 14, 2021 05:55am
- The government won a lawsuit filed by the government and the pharmaceutical industry over the cost-responsibility issue of follow-up measures for impurity drugs. On the 9th, the Civil Affairs Division 21 of the Seoul Central District Court sided with the NHIS in a lawsuit filed by Daewon Pharmaceutical and 35 other companies against the N
- Company
- K-mRNA Consortium support group to gain momentum
- by Nho, Byung Chul Sep 13, 2021 05:57am
- The research and development move of the K-mRNA Consortium formed to develop the next-generation COVID-19 vaccine is expected to gain further momentum. The consortium consisting of Hanmi, ST Pharm, GC Pharma and KIMCo announced on the 9th that Dong-A ST, a major pharmaceutical company in the development and production of specialized drugs in
- Company
- Pharma companies speed up delivery of urology combo drugs
- by Kim, Jin-Gu Sep 13, 2021 05:56am
- Korean pharmaceutical companies have been rushing to develop combination treatments for various urologic diseases, such as those for prostatic hypertrophy+erectile dysfunction or benign prostatic hyperplasia+overactive bladder. Many patients with urogenital disorders suffer various conditions at once, including enlarged prostate, erectile dys
